Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 8
Submit an article Journal homepage
842
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience

George NesrHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7147-843XView further author information
ORCID Icon,
Raakhee ShahHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Charalampia KyriakouHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Jonathan SiveHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Rakesh PopatHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Kwee YongHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Brendan WisniowskiHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Ke XuHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomORCID Iconhttps://orcid.org/0000-0002-2453-4475View further author information
ORCID Icon,
Ashu WechalekarHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Lydia LeeHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Stuart IngsHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Xenofon PapanikolaouHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Shameem MahmoodHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Annabel McmillanHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Jackie HorderHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Fiona NewrickHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Jotham MarfilHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Louise AinleyHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Samir AsherHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
,
Simon CheesmanHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
&
Neil RabinHaematology Department, University College London Hospitals NHS Foundation Trust, London, United KingdomView further author information
 show all
Pages 1465-1471 | Received 11 Jan 2023, Accepted 17 May 2023, Published online: 01 Jun 2023

References

  • Cancer Research UK. Myeloma incidence statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence#heading-One. [ppdated 2021, accessed 2022 Jul 19].
  • Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13(2):79–90.
  • Goldschmidt H, Lannert H, Bommer J, et al. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15(3):301–304.
  • Sive J, Cuthill K, Hunter H, et al. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum guideline. Br J Haematol. 2021;193(2):245–268.
  • Hussein MA, Bolejack V, Zonder JA, et al. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol. 2009;27(21):3510–3517.
  • Vesole DH, Zhang L, Flomenberg N, et al. A phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern cooperative oncology group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant. 2009;15(1):83–91.
  • Sirohi B, Powles R, Mehta J, et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant. 2005;36(1):19–24.
  • Jantunen E, Kuittinen T, Penttilä K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or = 65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant. 2006;37(10):917–922.
  • Talamo G, Rakszawski KL, Rybka WB, et al. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol. 2012;89(2):145–150.
  • Al Saleh AS, Sidiqi MH, Lee J, et al. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplant. 2020;55(11):2132–2137.
  • Mahindra A, Bolwell B, Rybicki L, et al. Timing of high dose melphalan (HDM) and outcomes for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). Biology of Blood and Marrow Transplantation. 2009;15(2):41–42.
  • Bergel F, Stock J. Cytotoxic alpha amino acids and peptides. Br Emp Cancer Campaign A. 1953;31:6–7.
  • Esma F, Salvini M, Troia R, et al. Melphalan hydrochloride for the treatment of multiple myeloma. Expert Opin Pharmacother. 2017;18(11):1127–1136.
  • Food & Drug Administrartion. Alkeran (melphalan) package insert. [accessed 203 Apr 6]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf.
  • Alberts DS, Chang SY, Chen H-G, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther. 1979;26(1):73–80.
  • Sarosy G, Leyland-Jones B, Soochan P, et al. The systemic administration of intravenous melphalan. J Clin Oncol. 1988;6(11):1768–1782.
  • Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13(7):1786–1799.
  • Reece PA, Hill HS, Green RM, et al. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol. 1988;22(4):348–352.
  • Kergueris MF, Milpied N, Moreau P, et al. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res. 1994;14(6):2379–2382.
  • Pinguet F, Martel P, Fabbro M, et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res. 1997;17(1):605–611.
  • Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–829.
  • San Miguel J, Lahuerta JJ, García-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1(1):28–36.
  • Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35(10):985–990.
  • Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2(6):947–952.
  • El Fakih R, Fox P, Popat U, et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin Lymphoma Myeloma Leuk. 2015;15(8):472–476.
  • Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28(33):4976–4984.
  • U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. [updated 2017, accessed 2022 Mar 19]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
  • Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955–2962.
  • Giralt S. 200 mg/m2 melphalan—the gold standard for multiple myeloma. Nat Rev Clin Oncol. 2010;7(9):490–491.
  • Sweiss K, Patel S, Culos K, et al. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant. 2016;51(10):1337–1341.
  • Abudayyeh A, Lin H, Mamlouk O, et al. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma. 2020;61(13):3101–3111.
  • Andronesi AG, Tanase AD, Sorohan BM, et al. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma. Cancer Med. 2019;8(6):3278–3285.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.